Exploring how the shape of peptides can improve cancer treatment
Identifying favorable regions of the conformational landscapes of peptides and peptidomimetics
This study is looking at how certain tiny proteins can help fight cancer by blocking harmful interactions that make cancer cells resistant to chemotherapy, with the goal of creating new treatments that work better for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10941025 on NIH RePORTER |
What this research studies
This research investigates the interactions between proteins in the human body, particularly focusing on how certain peptides can disrupt harmful protein interactions that contribute to cancer cell resistance to chemotherapy. By examining the conformational landscapes of these peptides, the study aims to design new therapeutic macromolecules that are both effective in binding to their targets and permeable enough to enter cells. The approach involves understanding the balance between rigidity and flexibility in peptide structures to enhance their therapeutic potential. Patients may benefit from new treatments that could improve the effectiveness of existing cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with melanoma or other cancers that exhibit resistance to chemotherapy.
Not a fit: Patients with non-cancerous conditions or those whose cancers do not involve the specific protein interactions being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective cancer treatments that enhance the efficacy of chemotherapy.
How similar studies have performed: Previous research has shown promise in using peptide-based therapies to disrupt protein interactions in cancer, indicating that this approach could be a valuable avenue for further exploration.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Knight, Abigail — Univ of North Carolina Chapel Hill
- Study coordinator: Knight, Abigail
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.